Navigation Links
ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
Date:8/7/2008

Positive Results to Date Drive Decision to Expand its Proprietary

Therapeutic Pipeline

ZURICH, Switzerland, Aug. 7 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that the company has raised an additional CHF 23M (USD 22M, EUR 14M) in an extended Series B venture round to expand its development pipeline. A global syndicate of current investors participated in this round including SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Bioventures, BioMedinvest and VI Partners.

This funding builds on the company's CHF 50M (USD 49M, EUR 31M) Series B round, which closed in August 2006 and has enabled the company to move its lead molecule, ESBA105, into clinical trials. ESBA105 is a single-chain antibody fragment directed against TNF-alpha and is developed in ophthalmic and additional inflammatory indications.

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, commented, "We are delighted to announce the expansion of our proprietary pipeline with this additional financing. This includes building broad franchises in ophthalmology, rheumatology and respiratory diseases for ESBA105 and additional antibody fragments. Since the announcement of the Series B financing in August 2006, ESBATech has made significant progress in R&D, including the demonstration in animal models that high concentrations of ESBA105 can be achieved in all segments of the eye with topical delivery via eye drops. Furthermore, we have advanced our anti-VEGF program to selection of a development candidate, ESBA903, a single-chain antibody that shows very high potency, stability and solubility, and will be developed for ophthalmic indications. Just like ESBA105, this antibody fragment will be delivered via eye drops and thus represents a true alternative to the current intra-vitreal injections of marketed anti-VEGF inhibitors."

Martin Gertsch, Chief Financ
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
2. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
3. Light Sciences Oncology Raises $40.1 Million in Series C Financing
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
6. EntreMed Raises $20 Million to Support Clinical Development Program
7. Globus Medical Raises $110 Million in Series E Financing Round
8. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
9. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
10. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
11. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...TSBURGH,Nov.24/PRNewswire/-- ,, WHAT:RomHoubens...winganautoaccident,wasactuallyfullyconsciousandawa...icasegment.TheDynaVoxEyeMaxwasfeaturedinthesegment...conditionscanunlockcommunication. ,, WHEN:GoodM...at www.dynavoxtech.com ,, WHO:RomHoubens...
(Date:11/24/2009)...DCLIFFLAKE,N.J.andNEWYORK,Nov.24/PRNewswire/-- Ei...dDrugAdministration(FDA)hasacceptedforreviewEisai,...74;(donepezilHClextendedrelease)tabletsforthetreat...ewhigherdoseformulationcontains23mgofdonepezilHCli...ystemthatallowsforgradualreleaseofthedrug.TheNDAis...
(Date:11/24/2009)...EIGH,N.C.,Nov.24/PRNewswire/--PharmaceuticalInstit...forthepharmaceuticalandbiotechindustry,todayannoun...ace .Thenew HospitalMarketplace e-courseisthenewes...M) series,acomprehensiveseriesofe-coursesdesignedt...etsknowledgeforcommercialprofessionals. ,, Then...
Breaking Medicine Technology:DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2Brain Training Keeps Older Drivers Safe Behind the Wheel 57315 1Brain Training Keeps Older Drivers Safe Behind the Wheel 57315 2Brain Training Keeps Older Drivers Safe Behind the Wheel 57315 3BioSpecifics Technologies Corp Stock Trading Halted Today 14076 1GENova and TheraGlass in advanced negotiations 57312 1GENova and TheraGlass in advanced negotiations 57312 2GENova and TheraGlass in advanced negotiations 57312 3
...--May 2, 2007 - Acorda Therapeutics, Inc.(R),(Nasd...ical trial,of Fampridine-SR in people with multipl...ogy meeting. Andrew Goodman, M.D.,Director of the...chester, presented top-line results on walking abi...ubject global impressions.,Dr. Goodman also presen...
...May 02, 2007 /PRNewswire-FirstCall/ --,Genelabs Te...on was,made today at the 20th International Confer...ngs, California, on a,non-nucleoside hepatitis C v...labs. , The oral presentation was given by Christo...istry at Genelabs, entitled,"GL59728: A Potent All...
Other Medicine Technology:Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3
(Date:11/24/2009)...USNewswire/--Parties,familydinners,andothergatheri...tthemerrimentcanchangetomiseryiffoodmakesyouorothe.../prnh/20090824/FDALOGO ) ,, Typicalsymptomsoffo...toms,whichcanstartanywherefromhourstodaysaftercont...sisthatpracticingfourbasicfoodsafetymeasurescanhel...
(Date:11/24/2009)...USNewswire/--IPROhasachieveditsthirdconsecutiveISO...dardfocusedonfulfillingcustomerrequirements,enhanc...nessperformance.CertificationtoISO9001:2008bySGSIn...ManagementSystem(QMS)haspassedarigorousexternalaud...ndAlbany,NewYorkaswellasatitsaffiliateLogiqual,LLC...
(Date:11/24/2009)...--Mostpeoplelookforwardtokickingofftheholidayseaso...andfamily.TheMacombCountyHealthDepartmentremindsyo...elingandbeinginlargegroupsareeasywaystospreadfluge... VACCINATION ,, Thefirstandmostimportantstepis...ainsttheH1N1strainoftheflu.TheMacombCountyHealthDe...
(Date:11/24/2009)...ire/--Nextmonth,UnitedHealthcarewilloffertwofreeMe...icanseniorsunderstandthebasicsofMedicare.Following...74;Goldclass,aLatin-infusedfitnessprogramthatblend... ,, UnitedHealthcarewilloffertheseseminarsinSpa...rningabouttheirhealthcareoptions. Thereareapproxi...
(Date:11/24/2009)...l/--CenteneCorporation(NYSE: CNC )todayannouncedth...neasoneoftwoCoordinatedCareOrganizationstoparticip...sippiCAN),acoordinatedcareprogramforMississippiMed...toexecuteacontractinwhichthecompanywillserveeligib...agnolia). ,, BasedinJackson,Miss.,Magnoliawillw...
Breaking Medicine News(10 mins):Health News:FDA Consumer Health Information: Food Safety Tips for Healthy Holidays 2Health News:IPRO Earns Third Consecutive Quality Management Certification 2Health News:Tips To Enjoy a Flu-Free Holiday Season 2Health News:UnitedHealthcare To Offer Seniors Hispanic-Centered Medicare Education Seminars Combined With a Latin-Themed Fitness Program 2Health News:Centene Corporation Receives Notification of Intent to Contract From the State of Mississippi 2
... Chicago, Ill.--The interaction of sex, age and e...val in metastatic colorectal cancer (MCRC) patient... Southern California (USC) and USC/Norris Comprehe...t gender also plays an important role in overall s...
... The passing of time makes ovaries lose their abi...rmones which regulate the menstrual cycle. In this...sical and psychical changes such as hot flushes, s...ain, the average age for the cessation of the mens...
...ETROIT, May 29 Caraco Pharmaceutical,Laboratories...he fourth,quarter and the year ended March 31, 200...ion, respectively, as compared to $32.7 million an...08,respectively, as compared to net income of $9.5...
...merifit Brands Educates Consumers about Urinary He... realize its,prevalence, urinary tract infections ...n in the body, and account for more than 8 million...lifetime.(2),However, many women do not realize th...
...esearch adds to what is known about relationship b... The risk of developing,type 2 diabetes in women ...ow cardiorespiratory fitness or higher Body Mass I... American,College of Sports Medicine (ACSM). An in...
...air of studies features biomechanical analysis of ...flip-flops as their primary footwear option during...and a change in their stride, according to,researc...s study began with the observation,that most peopl...
Other Medicine News:Health News:USC study finds sex, age and ethnicity assciated with colorectal cancer survival 2Health News:Post-menopausal therapy to improve women's quality of life 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 5Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 6Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 7Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 8Health News:AZO Answers the Burning Question: What's Up Down There? 2Health News:AZO Answers the Burning Question: What's Up Down There? 3Health News:AZO Answers the Burning Question: What's Up Down There? 4Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 2Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 3Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 4Health News:Flip-Flops, Heels Examined for Performance, Impact 2Health News:Flip-Flops, Heels Examined for Performance, Impact 3
Near Point Card/Newspaper 8 to 48 - BC2203
Near Point Diagnostic Card Set - BC11982
Near Point Card 4 1/2 to 24 PT - BC2202
... references to many common print sizes, from newsp...size. This provides the examiner a starting point ... black ink on yellow styrene for increased contras.... Other notations include Jaeger, M notation, lowe...
Medicine Products: